Year: 2021

Invalda INVL investor’s calendar for 2022

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Invalda INVL plans to publish information to investors in 2022 in accordance with the following calendar: 8 April 2022 – audited annual financial reports and annual report; 30 May 2022 – factsheet for 3 months of 2022; 31 August 2022 – semi–annual report of 2022; 30 November 2022 – factsheet for 9 months of 2022. Person authorised to provide additional information: Darius Šulnis President of Invalda INVL E-mail darius.sulnis@invl.com

Encryption Software Market to Increase Rapidly; Growing Popularity of Cloud Technology and Internet of things (IoT) to Contribute Impetus, states Fortune Business Insights™

Written by Customer Service on December 10, 2021. Posted in Mergers And Acquisitions.

Companies Profiled in the encryption software market are IBM Corporation (New York, United States), Symantec Corporation (Arizona, United States), Thales Group (La Défense, France), Microsoft Corporation (Washington, United States), Trend Micro Incorporated (Tokyo, Japan), Dell Technologies, Inc. (Texas, United States), Sophos Ltd. (Abingdon, United Kingdom), Check Point Software Technologies (Tel Aviv-Yafo, Israel), McAfee, Inc. (California, United States), WinMagic (Ontario, Canada) and others Pune, India, Dec. 10, 2021 (GLOBE NEWSWIRE) — The global encryption software Market size is expected to reach USD 24.94 billion by 2027, exhibiting a CAGR of 14.1% during the forecast period. The increasing number of data breaches, data security threats, and cyberattacks in organizations will enable speedy expansion of the market, states...

Novozymes announces closing of transaction of majority stake in Synergia Life Sciences

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Please read the full announcement in PDFAttachment2021_52_Acquisition_Synergia_Closed

INVL Technology investor’s calendar for 2022

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Closed–ended type investment company INVL Technology plans to publish information to investors in 2022 in accordance with the following calendar: 6 April 2022 – audited financial reports and annual report; 29 April 2022 – Net Asset Value and factsheet for 3 months of 2022; 26 August 2022 – Net Asset Value and semi–annual report of 2022; 31 October 2022 – Net Asset Value and factsheet for 9 months of 2022. The person authorized to provide additional information: Kazimieras Tonkūnas INVL Technology Managing Partner e-mail k.tonkunas@invltechnology.lt

Sampo plc’s share buybacks 09/12/2021

Written by Customer Service on December 10, 2021. Posted in Public Companies.

SAMPO PLC STOCK EXCHANGE RELEASE 10/12/2021 at 08:30 am Sampo plc’s share buybacks 09/12/2021 On 09/12/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code) 31,652 43.90 AQEU 47,855 43.78 CEUX 6,268 43.90 TQEX 131,674 43.79 XHELTOTAL 217,449 43.81 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021,...

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

Written by Customer Service on December 10, 2021. Posted in Public Companies.

REGULATED INFORMATIONArticle 14 of the Law of 2 May 2007 on disclosure of major holdingsGosselies, Belgium, 10 December 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 8 December 2021 indicating that the shareholdings held by Nyenburgh Holding NV have crossed above the threshold of 5% following the issuance of new shares of Bone Therapeutics via a private placement on 2 December 2021. The new shares were delivered to the participating investors on 7 December 2021. The notification dated 8 December 2021 contains the following information:Reason for the notification: Acquisition or disposal of voting securities or voting rights Notification by: A...

Coop Pank AS results for November 2021

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Coop Pank’s financial results in November 2021:In November, number of the bank’s clients increased by 2,400 and reached 112,400 by the end of the month. Over the year, customer base has grown by 34%. Volume of the bank’s customer deposits increased by 9 million euros, reaching 1.06 billion euros by the end of month. Deposits of corporate customers increased by 10 million and deposits of private customers by 5 million euros. The volume of deposits attracted from international platforms decreased by 6 million euros. Over the year, volume of bank deposits has grown by 42%. The bank’s loan portfolio increased by 45 million euros over the month and reached 914 million euros by the end of November. Business loans increased by 33 million euros, home loans by 9 million euros, consumer financing 1 million euros and leasing by...

Royal Vopak provides an update on the composition of its Executive Board

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Picture Royal Vopak – Michiel GilsingPicture Royal Vopak – Michiel GilsingRoyal Vopak provides an update on the composition of its Executive Board Michiel Gilsing to succeed Gerard Paulides as CFO of Royal Vopak COO Frits Eulderink nominated for a next termRotterdam, the Netherlands, 10 December 2021 The Supervisory Board of Royal Vopak will nominate Michiel Gilsing to succeed Gerard Paulides as CFO and member of the Executive Board, subject to shareholders approval and as per the date of the AGM scheduled for 20 April 2022. Frits Eulderink will be nominated for a next term as COO and member of the Executive Board. Gerard joined the Executive Board in February 2018 and his four-year term ends in April 2022. He remains available to the incoming CFO and to the Royal Vopak Board to assist with the transition...

Egide: Egide Group order entry is accelerating in Q4 21

Written by Customer Service on December 10, 2021. Posted in Public Companies.

Bollène, December 10,2021 – 07 :00am (CET)Press Release Egide Group order entry is accelerating in Q4 21,preparing for continued growth in 2022.New customer contracts were secured in 4thquarter 2021, comforting the Egide Group backlog for 2022. Egide customers globally unaffected by the current shortage of electronic components Egide USA’s Cambridge Plant at Full Production Capacity Group enters 2022 with confidenceWhile the world economy is worried about the resurgence of the epidemic, Egide Group is approaching 2022 with serenity after securing new business engagements these recent weeks.In Europe:Several orders for a total of €2.4 million revenue in 2022 have been received since October from Defense customers in Israel: multiple new projects which co-development started few years ago with one of Egide’s important customer...

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

Written by Customer Service on December 10, 2021. Posted in Public Companies.

–Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- –52-Week Data from the Phase 3 PRIMROSE studies of linzagolix for the treatment of uterine fibroids demonstrating sustained safety and efficacy results at 52 weeks to be presented orally– –Long-term follow–up data from Phase 2b EDELWEISS study of linzagolix for the treatment of endometriosis demonstrating bone mineral density recovery to be presented orally– Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland December 10, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced upcoming presentations...

Year: 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals